When Breast Cancer Needs — a PET-CT Scan

Not automatically. If your diagnosis is early-stage breast cancer — Stage I or II without high-risk features — your oncologist is following evidence-based guidelines in not recommending it. Requesting a scan that is not indicated does not produce better information; it adds cost, radiation, and the possibility of incidental findings that generate anxiety without changing your management. If you want to understand why staging is considered complete without it, ask your oncologist to explain which scans have been done and what they showed. A clear answer to that question is reasonable to expect.

Finding distant spread changes the stage from locally advanced to metastatic, and that changes the treatment approach. Surgery to remove the primary tumour is generally not the priority when cancer has spread widely — systemic treatment takes precedence. This is a significant change and it is natural to find it frightening. But it is also information that prevents an operation from being done that would carry real risks without providing benefit. Your oncologist will explain what the finding means specifically for your situation, and what the treatment aim will be.

Yes. PET-CT is a genuinely useful staging tool, but it has real limitations. It is less sensitive for very small deposits. It can miss brain metastases, which are better imaged by MRI. And it is a functional scan, not a definitive diagnostic one — a finding that shows high metabolic activity on PET still needs tissue confirmation before treatment decisions are made on it. Your oncologist will tell you if additional imaging is needed alongside or after the PET to give a complete picture.

Sometimes. If you received neoadjuvant chemotherapy — chemotherapy given before surgery — a repeat scan may be used to assess how well the cancer responded to treatment. This is called metabolic response assessment. Whether a repeat scan is done depends on your oncologist's judgement about what the result would change in your management, and it is not routine in all cases. Ask your oncologist at the start of treatment what the plan for response assessment will be, so you are not left uncertain about it mid-way through.

The radiation dose is real and worth taking seriously, but it is at a level considered clinically acceptable given the value of the information the scan provides. The tracer — a radioactive form of glucose — clears from your body within hours. Your oncologist would not recommend the scan if the benefit in your situation did not justify the exposure. If you are pregnant or breastfeeding, tell your team immediately — imaging decisions change significantly in those situations, and there may be alternatives.

Tell your oncologist what you are worried about and ask them to explain the reasoning. A staging plan should be explainable, and your concern deserves a direct answer — not reassurance without a reason. If you remain unsure after that conversation, a second opinion from another oncologist at a cancer centre is entirely reasonable. What is not productive is arranging imaging privately without that clinical discussion, because the results arrive without context and can be difficult to interpret on their own.